Last Updated on March 18, 2024 by The Health Master
USFDA Approval
In the ever-evolving pharmaceutical landscape, Strides Pharma Science takes a giant leap forward with its subsidiary, Strides Pharma Global Pte. Limited, Singapore, receiving USFDA approval for gabapentin tablets, marking a significant milestone in the company’s journey.
Understanding the Approval
Exploring the specifics of the approval process, bioequivalence, and therapeutic equivalency to the Reference Listed Drug (RLD) Neurontin tablets are crucial aspects.
We delve into the implications of this approval for Strides Pharma Science.
Market Dynamics
Unveiling the market dynamics surrounding gabapentin tablets, with a focus on its substantial market size of approximately US$ 140 million, according to IMS.
How does this approval enhance Strides Pharma’s position in this lucrative market?
Portfolio Strengthening
Examining the strategic move of Strides Pharma in bolstering its gabapentin portfolio.
We explore how this approval complements the existing approval of gabapentin capsules, boasting a market size of US$ 208 million.
Manufacturing Hub: Puducherry Facility
An insight into the company’s manufacturing prowess at the Puducherry facility, where the gabapentin tablets will be produced.
Understanding the significance of local production in the pharmaceutical industry.
Gabapentin Unveiled: Therapeutic Insights
A closer look at gabapentin, its role as an anticonvulsant medication, and its primary use in treating partial seizures and neuropathic pain.
Unraveling its significance in managing conditions such as diabetic neuropathy, postherpetic neuralgia, and central pain.
Regulatory Milestones: USFDA and Beyond
Reflecting on the broader implications of USFDA approval and their role in shaping Strides Pharma‘s trajectory.
What regulatory milestones can we anticipate in the future?
Future Outlook: Gabapentin Tablets
Gazing into the crystal ball, we explore the future outlook for gabapentin tablets, considering market trends, patient needs, and potential expansions in the company’s gabapentin portfolio.
Patient-Centric Approach
Shifting the focus to the end-users, we discuss the impact of Strides Pharma’s gabapentin tablets on patients, emphasizing a patient-centric approach in pharmaceutical advancements.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
CDSCO approval granted for Plazomicin injection in India
USFDA approval granted for Isosorbide Mononitrate ER Tablets
The Future of Drug Approval: Embracing the USFDA’s RRA
USFDA Approval granted for Generic Dronedarone Tablets
USFDA approval granted for Pregabalin capsule: Strides Pharma
NPPA fixed Ceiling price of 6 scheduled formulations: February 2024
IPC releases draft guidelines to include Disinfectants & Antiseptics in IP
No More Discount Banners for Pharmacies in Maharashtra
Aurobindo Pharma’s Arm gets 7 observations from USFDA
NPPA revised Ceiling price of 25 scheduled formulations: February 2024
Pharma Transparency: The Need for Clearer Eye Drops Packaging
A Critical Analysis of latest Homoeopathy Notification No. GSR 98(E) dated 02-02-2024
CDSCO’s Revised Guidance on Post Approval Changes in Biological Products
Delay in Medical Device Officers Recruitment: A Call for Swift Action
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
